Clinical trials: Prostate Specific Antigen
Prostate Cancer
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA
This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance.
- Trial name
- NCT06600698
- Testing
- INM176
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Milton S. Hershey Medical Center
Prostatic Neoplasms, Prostate-Specific Antigen
Prognostic Study of Prostate Cancer Via Dynamic Change of PSA in Peritoneal Drainage Fluid After Radical Prostatectomy
This study investigates the prognostic value of dynamic changes in Prostate-Specific Antigen (PSA) levels found in the peritoneal drainage fluid after radical prostatectomy.
- Trial name
- NCT06608225
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Prostate Cancer
GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer
The purpose of this study is to assess the effect of GTx-758 on Serum Prostate-specific antigen (PSA) levels in men with castrate resistant prostate cancer who are maintained on androgen deprivation therapy (Serum PSA response…
- Trial name
- NCT01420861
- Testing
- GTx-758
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- GTx
Prostate Cancer
A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer
Prostate cancer is the second leading cause of cancer death in men. According to estimates by the American Cancer Society Prostate for 2022, about 268,490 men would be diagnosed with prostate cancer and 34,500 would die from the…
- Trial name
- NCT05900973
- Testing
- Darolutamide Oral Tablet [Nubeqa]
- Where
- Brazil
- Volunteers
- 19 people
- Sponsor
- D'Or Institute for Research and Education
Malignancy
Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
In this study, Al18F-PSMA-BCH PET/CT will be performed in patients with prostate specific membrane antigen positive tumor, to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.
- Trial name
- NCT05761366
- Testing
- Al18F-PSMA-BCH PET/CT
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Prostate Cancer
A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy
To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with prostate cancer.
- Trial name
- NCT01302041
- Testing
- Enzalutamide
- Where
- 12 sites in Belgium, Czechia and 2 more
- Volunteers
- 67 people
- Sponsor
- Astellas Pharma Inc
Prostate Infections
Impact of Antibiotic Treatment on Prostate-Specific Antigen (PSA) Variability
Ciprofloxacin hydrochloride has been approved by the Food and Drug Administration (FDA) for the treatment of mild to moderate infections, including prostate infections.
- Trial name
- NCT00596453
- Testing
- Ciprofloxacin hydrochloride
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Johns Hopkins University
Advanced and/or Metastatic Solid Tumours
A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions
CB307 is a trispecific Humabody® targeting CD137; PSMA; and human serum albumin (HSA) undergoing Phase 1 assessment in patients with PSMA+ solid tumours.
- Trial name
- NCT05836623
- Testing
- Radiolabelled CB307, CB307
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Crescendo Biologics Ltd.
Prostate Cancer, Prostatic Neoplasms
Test Semiquantitative Prostate Specific Antigen (PSA)
The aim of the study is to compare the diagnostic performances of a simple and rapid PSA assay on whole blood to the standard plasma PSA assay.
- Conditions
- Prostate Cancer, Prostatic Neoplasms, Prostatic Diseases
- Trial name
- NCT00853710
- Testing
- PSA assay
- Where
- France
- Volunteers
- 94 people
- Sponsor
- Institut Curie
Prostatic Neoplasm
A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
One current hypothesis as to what limits duration of initial hormone response is the rapid emergence of hormone resistant prostate carcinoma cells.
- Trial name
- NCT00001266
- Testing
- Suramin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Informed Decision-Making Regarding Prostate Specific Antigen (PSA) Screening in 50-70 Year Old Latino Men
The purpose of this intervention trial is aiming to increase inform decision- making in Latino men regarding prostate cancer screening.
- Trial name
- PSA (NCT00761124)
- Testing
- Intervention Session, Printed Material
- Where
- United States
- Volunteers
- 1,006 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer, Prostate Cancer Metastatic Disease
Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level (PSA) Remains >0,2 ng/ml After Six Months of Dual Antihormonal Therapy Will Receive Radiotherapy to the Prostate and Radiotherapy to Refractory Metastases
The goal of this clinical trial is to learn if radiotherapy to the prostate and PET-positive (positron emission tomography) metastasis will lead to radiological response on PSMA-PET (prostate specific membrane antigen-PET).
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic Disease, Prostate Cancer Metastatic to Bone
- Trial name
- RIALTO (NCT07644754)
- Testing
- Radiotherapy to the prostate and to PSMA-PET positive metastases
- Volunteers
- 27 people
- Sponsor
- University Hospital Tuebingen
Prostate Adenocarcinoma, Prostate Cancer
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
The goal of this research study is to determine whether hormonal therapies used early in the course of prostate cancer could increase the amount of Prostate-Specific Membrane Antigen (PSMA) as detected by PET/CT scans for…
- Conditions
- Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Trial name
- NCT05683964
- Testing
- Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi], Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Beth Israel Deaconess Medical Center
Prostatic Diseases
Character Traits and Stress in Suspected Prostate Cancer
It has previously been reported that men with prostate cancer are 1 ) reduced quality of life after diagnosis and treatment, 2 ) neuroticism increases the reduction in QoL related to treatment side effects, and 3) often have very…
- Trial name
- NCT02031029
- Where
- 2 sites in Norway
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Helse Stavanger HF
Inflammatory Bowel Diseases, Prostate Cancer
The Effect of IBD Flares on Serum PSA
This study will measure Prostate Specific Antigen (PSA) values in men with Inflammatory Bowel Disease (IBD) before, during, and following a flare.
- Trial name
- NCT03558048
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Northwestern University
Prostate Cancer Diagnosis
PSMA PET Scan and mpMRI for Prostate Cancer Detection
Prospective, randomized, phase 2 clinical trial to determine if PSMA PET imaging plus mpMRI improves detection of clinically significant prostate cancer as compared to mpMRI alone.
- Trial name
- NCT05820724
- Testing
- PSMA PET scan, No PSMA PET, 18F- DCFPyl Injection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- VA Greater Los Angeles Healthcare System
PSA, Prostate Cancer
Smart Prostate Specific Antigen (PSA) Screening Study
This intervention includes the introduction of the Prostate Cancer Working Group (PCWG )Smart PSA Screening Guidelines and implementation of patient navigation/ care coordination for men with elevated PSA (>4.0 ng/mL).
- Trial name
- NCT04782713
- Testing
- Completing surveys
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Illinois at Chicago
Prostate Carcinoma
Prostate Specific Antigen Levels of Individuals Living in Rural Areas
It was planned in cross-sectional design in order to determine the specific prostate antigen level and some characteristics and the relationship evaluations and prostate specific antigen formation in individuals living in rural…
- Trial name
- NCT06900348
- Testing
- PSA-Activated PSA-PAH1
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- Suleyman Demirel University
Prostate Cancer
Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III)
Prostate cancer remains one of the leading causes of cancer-related morbidity and mortality among men. While PSA-based screening has been associated with reduced prostate cancer mortality, it also results in substantial…
- Trial name
- Visioning III (NCT07762911)
- Testing
- MRI
- Where
- Switzerland
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Prostate-specific Membrane Antigen, mCRPC or Advanced/Metastatic Solid Tumors
Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors
multi-centre, prospective, diagnostic trial to evaluate the Prostate-Specific Membrane Antigen (PSMA-antigen) over-expression in metastatic castration resistant prostate cancer (mCRPC) and in advanced/metastatic solid tumors…
- Trial name
- BASKET PSMA (NCT03453528)
- Testing
- 68Ga-PSMA
- Where
- Italy
- Volunteers
- 1,225 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS